The linear progression through generations of BTK inhibitors may be a flawed strategy, as indefinite kinase blocking is unsustainable. The future likely lies in BTK degraders, a new drug class that eliminates the target protein entirely, offering a novel approach to overcoming resistance instead of just inhibiting the protein.

Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.

BTK degraders work despite most kinase inhibitor resistance mutations. However, resistance to degraders themselves alters the BTK binding pocket so significantly that subsequent targeting with any BTK kinase inhibitor is unlikely to be effective, positioning them as a potential end-of-line therapy.

A new agent, BGP-16673, works by destroying the BTK protein rather than just inhibiting it. This novel "degrader" mechanism is highly effective (75% response rate) in CLL patients who have developed resistance to covalent (e.g., ibrutinib), non-covalent (pirtobrutinib), and BCL-2 inhibitors, offering a new path for refractory disease.

Despite advancements from first-generation (ibrutinib) to second-generation (acalabrutinib) BTK inhibitors, a consistent pattern emerges: the rate of complete responses plateaus around 36% over time. This suggests a potential biological limit for this class of drugs when used as monotherapy in CLL.

In CLL, Progression-Free Survival (PFS) is a misleading metric for clinical benefit. Time-To-Next-Treatment (TTNT) is often much longer because patients can have biochemical or radiological progression by IWCLL criteria but remain asymptomatic and clinically well, delaying the need for a new therapy.

Modern therapies have dramatically improved survival for high-risk CLL patients. However, this group paradoxically represents the largest unmet need, as they are the most likely to develop resistance to the main drug classes over decades, driving research into novel mechanisms like degraders and non-covalent inhibitors.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

While the continuous BTK inhibitor zanubrutinib showed longer progression-free survival, this efficacy came with a significant safety trade-off. It led to a 47% rate of serious adverse events compared to 24% for the fixed-duration acalabrutinib-venetoclax combination in the indirect analysis.